Luteal support: Progestogens for pregnancy protection

Maturitas

Volumn 65, Issue SUPPL. 1, 2009, Pages

  Daya, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Dydrogesterone; Luteal support; Miscarriage; Pregnancy; Progesterone; Progestogen

Indexed keywords

DYDROGESTERONE; ESTROGEN; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE;

ARTICLE; CLINICAL TRIAL; CORPUS LUTEUM; CYTOKINE PRODUCTION; ENDOMETRIUM; FEMALE INFERTILITY; GRANULOSA CELL; HUMAN; INTRAHEPATIC CHOLESTASIS; LUTEAL PHASE; LUTEINIZATION; OOCYTE RETRIEVAL; OVULATION; PLACENTA; PREGNANCY; PROGESTERONE RELEASE; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; CORPUS LUTEUM; DYDROGESTERONE; EMBRYO IMPLANTATION; FEMALE; HUMANS; LUTEAL PHASE; PREGNANCY; PROGESTERONE; PROGESTINS; REPRODUCTIVE CONTROL AGENTS; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 72649088595     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.09.012     Document Type: Article

References (56)

1. Scott R., Navot D., Liu H.C., and Rosenwaks Z. A human in vivo model for the luteoplacental shift. Fertil Steril 56 (1991) 481-484
2. Nakajima S.T., Nason F.G., Badger G.J., and Gibson M. Progesterone production in early pregnancy. Fertil Steril 55 (1991) 516-521
3. Szekeres-Bartho J., Wilczynski J.R., Basta P., and Kalinka J. Role of progesterone and progestin therapy in threatened abortion and preterm labour. Front Biosci 13 (2008) 1981-1990
4. Druckmann R., and Druckmann M.A. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 97 (2005) 389-396
5. Simoncini T., Caruso A., Giretti M.S., et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 86 Suppl. 4 (2006) 1235-1242
6. Sladek S.M., Magness R.R., and Conrad K.P. Nitric oxide and pregnancy. Am J Physiol 272 (1997) R441-R463
7. Hill N.C., Selinger M., Ferguson J., López Bernal A., and Mackenzie I.Z. The physiological and clinical effects of progesterone inhibition with mifepristone (RU 486) in the second trimester. Br J Obstet Gynaecol 97 (1990) 487-492
8. Donaghay M., and Lessey B.A. Uterine receptivity: alterations associated with benign gynaecological disease. Sem Reprod Med 25 (2007) 461-475
9. Wilcox A.J., Baird D.D., and Weinberg C.R. Time of implantation of the conceptus and loss of pregnancy. New Engl J Med 340 (1999) 1796-1799
10. Lessey B.A. The role of the endometrium during embryo implantation. Hum Reprod 15 Suppl. 6 (2000) 39-50
11. Creus M., Ordi J., Fábregues F., Casamitjana R., Carmona F., and Cardesa A. The effect of different hormone therapies on integrin expression and pinopode formation in the human endometrium: a controlled study. Hum Reprod 18 (2003) 683-693
12. Nikas G., Drakakis P., Loutradis D., et al. Uterone pinopodes as markers of the 'nidation window' in cycling women receiving exogenous oestradiol and progesterone. Hum Reprod 10 (1995) 1208-1213
13. Apparao K.B.C., Murray M.J., Fritz M.A., et al. Osteopontin and its receptor αvβ3 integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differently. J Clin Endocrinol Metab 86 (2001) 4991-5000
14. Lessey B.A., and Castelbaum A.J. Integrins and implantation in the human. Rev Endocrin Metab Dis 3 (2002) 109-119
15. Lessey B.A. Two pathways of progesterone action in the human endometrium: implications for implantation and contraception. Steroids 68 (2003) 809-815
16. Rowan K., Meagher S., Teoh M., Vollenhoven B., Choong S., and Tong S. Corpus luteum across the first trimester: size and laterality as observed by ultrasound. Fertil Steril 90 (2008) 1844-1847
17. Csapo A.I., Pulkkinen M.O., Ruttner B., Sauvage J.P., and Wiest W.G. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 112 (1972) 1061-1067
18. Csapo A.I., Pulkkinen M.O., and Kaihola H.L. The relationship between the timing of luteectomy and the incidence of complete abortions. Am J Obstet Gynecol 118 (1974) 985-989
19. Csapo A.I., Pulkkinen M.O., and Wiest W.G. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 115 (1973) 759-765
20. Tamura H., Takasaki A., Taniguchi K., Matsuoka A., Shimamura K., and Sugino N. Changes in blood-flow impedance of the human corpus luteum throughout the luteal phase and during early pregnancy. Fertil Steril 90 (2008) 2334-2339
21. Balasch J., and Vanrell J.A. Corpus luteum insufficiency and fertility: a matter of controversy. Hum Reprod 2 (1987) 557-567
22. Balasch J., Vanrell J.A., Márquez M., Burzaco I., and González-Merlo J. Dehydrogesterone versus vaginal progesterone in the treatment of the endometrial luteal phase deficiency. Fertil Steril 37 (1982) 751-754
23. Tavaniotou A., Smitz J., Bourgain C., and Devroey P. Ovulation induction disrupts luteal phase function. Ann NY Acad Sci 943 (2001) 55-63
24. Olivennes F. The use of gonadotropin-releasing hormone antagonist in ovarian stimulation. Clin Obstet Gynecol 49 (2006) 12-22
25. DiLuigi A.J., and Nulsen J.C. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function. Curr Opin Obstet Gynecol 19 (2007) 258-265
26. Garcia J., Jones G.S., Acosta A.A., and Wright Jr. G.L. Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil Steril 36 (1981) 565-572
27. Daya S., and Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 3 (2004) CD004830
28. Tarlatzis B.C., Fauser B.C., Kolibianakis E.M., Diedrich K., Rombauts L., and Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 12 (2006) 333-340 [Erratum in: Hum Reprod Update 2006;12:797]
29. Bacq Y., Sapey T., Bréchot M.C., Pierre F., Fignon A., and Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology 26 (1997) 358-364
30. Chakravarty B.N., Shirazee H.H., Dam P., Goswami S.K., Chatterjee R., and Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 97 (2005) 416-420
31. Chakravarty B.N., Dam P., Goswami S.K., Ghosh S., and Chattopadhyay R. Oral dydrogesterone versus vaginal micronized progesterone as luteal phase support in ART cycles-evaluation based on correction of hormone profile and clinical outcome. Hum Reprod 20 Suppl. 1 (2005) 1139
32. Patki A., and Pawar V.C. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol 23 Suppl. 1 (2007) 68-72
33. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
34. Gruber I., Just A., Birner M., and Lösch A. Serum estradiol/progesterone ratio on day of embryo transfer may predict reproductive outcome following controlled ovarian hyperstimulation and in vitro fertilization. J Exp Clin Assist Reprod 4 (2007) 1-6
35. Smitz J., Bourgain C., van Waesberghe L., Camus M., Devroey P., and van Steirteghem A.C. A prospective randomized study on oestradiol supplementation in addition to intravaginal micronized progesterone in buserelin and HMG-induced superovulation. Hum Reprod 8 (1993) 40-45
36. Lewin A., Benshushan A., Mezker E., Yanai N., Schenker J.G., and Goshen R. The role of estrogen support during the luteal phase of in vitro fertilization-embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertil Steril 62 (1994) 121-125
37. Farhi J., Weissman A., Steinfeld Z., Shorer M., Nahum H., and Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril 73 (2000) 761-766
38. Tay P.Y., and Lenton E.A. Inhibition of progesterone secretion by oestradiol administered in the luteal phase of assisted conception cycles. Med J Malaysia 58 (2003) 187-195
39. Gorkemli H., Ak D., Akyurek C., Aktan M., and Duman S. Comparison of pregnancy outcomes of progesterone or progesterone + estradiol for luteal phase support in ICSI-ET cycles. Gynecol Obstet Invest 58 (2004) 140-144
40. Lukaszuk K., Liss J., Lukaszuk M., and Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril 83 (2005) 1372-1376
41. Fatemi H.M., Kolibianakis E.M., Camus M., et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Hum Reprod 21 (2006) 2628-2632
42. Engmann L., DiLuigi A., Schmidt D., Benadiva C., Maier D., and Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril 89 (2008) 554-561
43. Ceyhan S.T., Basaran M., Kemal Duru N., Yilmaz A., Göktolga U., and Baser I. use of luteal estrogen supplementation in normal responder patients treated with fixed multi-dose GnRH antagonist: a prospective randomized controlled study. Fertil Steril 89 (2008) 1827-1830
44. Serna J., Cholquevilque J.L., Cela V., Martínez-Salazar J., Requena A., and Garcia-Velasco J.A. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial. Fertil Steril 90 (2008) 2190-2195
45. Beckers N.G., Macklon N.S., Eijkemans M.J., et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 88 (2003) 4186-4192
46. Tavaniotou A., and Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reprod Biomed Online 13 (2006) 326-330
47. Aboulghar M.A., Amin Y.M., Al-Inany H.G., et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod 23 (2008) 857-862
48. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol 13 (2001) 219-227
49. Raghupathy R., and Kalinka J. Cytokine imbalance in pregnancy complications and its modulation. Front Biosci 13 (2008) 985-994
50. Raghupathy R., Makhseed M., Azizieh F., Omu A., Gupta M., and Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Human Reprod 15 (2000) 713-718
51. Raghupathy R., Al Mutawa E., Makhseed M., Azizieh F., and Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG 112 (2005) 1-6
52. El-Zibdeh M.Y. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 97 (2005) 431-434
53. Swyer G.I., and Daley D. Progesterone implantation in habitual abortion. Br Med J 1 (1953) 1073-1077
54. Goldzieher J.W. Double-blind trial of a progestin in habitual abortion. JAMA 188 (1964) 651-654
55. Levine L. Habitual abortion. A controlled study of progestational therapy. West J Surg Obstet Gynecol 72 (1964) 30-36
56. El-Zibdeh M.Y. Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with a progesterone (dydrogesterone) and human chorionic gonadotrophin (hCG). Fertil Steril 70 1S (1998) 77-78